Therapeutic effect of neoadjuvant chemotherapy combined with docetaxel,oxaliplatin and capecitabine in the treatment of advanced gastric cancer

Objective: To investigate the therapeutic effect and adverse drug reactions(ADRs) of neoadjuvant chemotherapy combined with docetaxel,oxaliplatin and capecitabine(DOX regimen) in the treatment of advanced gastric cancer.Methods: One hundred and eighty-six patients with advanced gastric cancer in Department of Gastrointestinal Surgery,Changzheng Hospital,Second Military Medical University from 2008-06-01 to 2011-05-31 received neoadjuvant chemotherapy.Neoadjuvant chemotherapy regimen was as follows:75 mg/m2 docetaxel(iv gtt,on day 1),130 mg/m2 oxaliplatin(iv gtt,on day 2),1 000 mg/m2 capecitabine(bid,po,on days 1-14) with 3 weeks as one treatment course,totalling 2-3 courses.And the patients received surgery,2-3 weeks after termination of chemotherapy.Results: Total response rate was 67.8%,complete response rate was 3.8%(7 patients),partial response rate was 64.0%(119 patients).Total resection rate was 81.5%,R0 resection rate was 80.4%.Main ADRs were myelosuppression,nausea and vomiting.Conclusion: Overall curative resection rate was increased in patients with advanced gastric cancer,after neoadjuvant chemotherapy with docetaxel,oxaliplatin and capecitabine.The ADRs rate of neoadjuvant chemotherapy was within acceptable range.